Lupin Limited — Others, 20-08-2025: Change in Director(s)

Lupin's Board has approved the re-appointment of Mr. Mark D. McDade as an Independent Director for a second five-year term, effective January 28, 2026, until January 27, 2031. This decision, following review by the Nomination and Remuneration Committee, is subject to shareholder approval. Mr. McDade brings over four decades of biopharmaceutical industry experience, including expertise in corporate governance, leadership, and strategic management. His continued involvement will ensure stability and experienced oversight on the board, crucial for the company's long-term direction and shareholder value.